Stock Price Quote

GUFIC BIOSCIENCES LTD.

NSE : GUFICBIOBSE : 509079ISIN CODE : INE742B01025Industry : Pharmaceuticals & DrugsHouse : Private
BSE315.55-5.3 (-1.65 %)
PREV CLOSE ( ) 320.85
OPEN PRICE ( ) 318.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2263
TODAY'S LOW / HIGH ( )314.00 319.20
52 WK LOW / HIGH ( )177.1 364
NSE315.45-5.45 (-1.7 %)
PREV CLOSE( ) 320.90
OPEN PRICE ( ) 320.90
BID PRICE (QTY) 315.45 (511)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 43983
TODAY'S LOW / HIGH( ) 313.70 320.90
52 WK LOW / HIGH ( )177.65 364.9
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 23-07 1984
Management Info
Jayesh P Choksi - Chairman Jayesh P Choksi - Managing Director
Registered Office

Address Shop - 37, First Floor,Kamala Bhavan I I,Swami Nityanand Road, Andheri East,
Mumbai,
Maharashtra-400069

Phone

Email info@guficbio.com

Website www.guficbio.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

09Jan Gufic Biosciences informs about compli
Gufic Biosciences has informed that it enclosed certificate received fro..
23Nov Gufic Biosciences informs about transc
In continuation to communication dated November 17, 2023 on Earnings Con..
22Nov Intimation Of Incorporation Of Subsid
Intimation of incorporation of Subsidiary Company is attached herewith.
20Nov Gufic Biosciences incorporates subsidi
Gufic Biosciences has incorporated a subsidiary Company in India namely..
20Nov Gufic Biosciences inches up on incorpo
Gufic Biosciences is currently trading at Rs. 297.55, up by 0.75 points..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit222.57797.05
Gross Profit 295.58 1067.21
Operating Profit 368.791372.25
Net Sales 2017.786906.21

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  28639.35 (0.55%)
M.Cap ( in Cr)60856.62
Bharat Parenterals (BSE)
peergroup  1147.65 (10.28%)
M.Cap ( in Cr)667.89
Astrazeneca Pharma I (BSE)
peergroup  5567.65 (1.95%)
M.Cap ( in Cr)13919.13
Neuland Laboratories (BSE)
peergroup  7063.75 (1.37%)
M.Cap ( in Cr)9062.71
Mankind Pharma (BSE)
peergroup  2097.55 (1.58%)
M.Cap ( in Cr)84025.43

Shareholding Pattern

PROMOTERS 72.51%
NON-INSTITUTION 25.29%
MUTUAL FUNDS/UTI 1.6%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Gufic Biosciences Ltd.

Gufic Biosciences Ltd. was incorporated in the year 1984. Its today's share price is 315.55. Its current market capitalisation stands at Rs 3164.26 Cr. In the latest quarter, company has reported Gross Sales of Rs. 8008.26 Cr and Total Income of Rs.6931.95 Cr. The company's management includes Ami Shah, Balram Singh, Rabi N Sahoo, Shrirang V Vaidya, Shreyas K Patel, Anu S Aurora, Gopal Daptari, Dilip B Ghosh, Pankaj J Gandhi, Pranav J Choksi, Jayesh P Choksi, Jayesh P Choksi.

It is listed on the BSE with a BSE Code of 509079 , NSE with an NSE Symbol of GUFICBIO and ISIN of INE742B01025. It's Registered office is at Shop - 37, First Floor,Kamala Bhavan I I,Swami Nityanand Road, Andheri EastMumbai-400069, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Mayur Chokshi & Co, Mittal Agarwal & Co, SHR & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.